A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled CSJ117 in Adults With Chronic Obstructive Pulmonary Disease (COPD)

This is a Phase 2 study in patients with chronic obstructive pulmonary disease (COPD) to assess the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and safety of two dose levels of CSJ117 in comparison to placebo. For this, the impact of CSJ117 on disease symptom burden and lung function will be explored.

Start Date24 Sep 2021

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NCT04946318

/ TerminatedPhase 2

A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients ≥18 Years of Age

The purpose of this study is to provide safety and tolerability, pharmacokinetics and immunogenicity data for multiple CSJ117 doses inhaled once daily compared with placebo, in adult asthma participants treated with medium or high dose ICS plus LABA alone or with additional asthma controllers (additional controllers allowed: LTRA, LAMA, Theophylline and its derivatives), who have completed the prior phase llb study CCSJ117A12201C (NCT04410523).

Start Date08 Sep 2021

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NCT04410523

/ TerminatedPhase 2

A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients ≥ 18 Years of Age With Severe Uncontrolled Asthma.

The purpose of this study is to determine the efficacy and safety of multiple CSJ117 doses (0.5; 1; 2; 4 and 8 mg) inhaled once daily compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult patients with uncontrolled asthma with respect to change from baseline in FEV1 at the end of 12 weeks of treatment.

Start Date09 Sep 2020

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

100 Clinical Results associated with Ecleralimab

100 Translational Medicine associated with Ecleralimab

100 Patents (Medical) associated with Ecleralimab

Literatures (Medical) associated with Ecleralimab

07 May 2025·Cureus Journal of Medical Science

Advancements in Biologic Therapies for Pediatric Asthma: Emerging Therapies and Future Directions

Review

Author: Vivas Monzón, María Alejandra ; Rengel Chalco, María José ; Anda Suárez, Pablo Xavier ; Méndez, Nayely García ; Romero, Uziel Márquez ; Zavala Gama, Ciro Gonzalo

This review aims to analyze biologic treatments for pediatric asthma, along with their effects on T2-high inflammation, together with outcomes of omalizumab, mepolizumab, and dupilumab. This review examined recent biomarker advancements, together with endotype patterns, while analyzing early treatment opportunities that might transform asthma's natural course. In conclusion, the advancement in biologic therapies is offering significant progress for personalized severe asthma treatment among pediatrics, especially for the T2-high endotype. Biologics such as omalizumab, mepolizumab, dupilumab, benralizumab, and tezepelumab have been reported to reduce severe asthma exacerbations, with reassuring short-term safety profiles among children and adolescents (pediatrics). However, the treatment efficacy of these biologics is limited for T2-low and non-T2 asthma endotypes, emphasizing the need for new biologic therapies that target these endotypes. Literature review also highlights the emerging treatment regimens for non-T2 endotypes, such as tezepelumab, ecleralimab, and astegolimab (IL-33), which influence both T2 and non-T2 pathways. The integration of precision medicine and multi-omics data specific to patients is not only providing promising results, but also helping to refine patient selection and patient-specific treatment. Furthermore, the identification of novel predictive biomarkers through advanced omics methods is essential for a more personalized approach. Ultimately, the continued advancement and strategic implementation of biologic therapies hold the potential to revolutionize the management of severe pediatric asthma, leading to reduced exacerbations and corticosteroid use, improved quality of life, and more precise treatment strategies tailored to individual patient profiles. Moreover, future research should continue to address the challenges related to long-term safety, cost-effectiveness, and equitable access, which are vital to realizing the true potential of biologic therapies in treating pediatric asthma.

02 Jan 2024·Expert opinion on investigational drugs

Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review

Review

Author: Bettin, Federica Roberta ; D’Auria, Maria ; Rogliani, Paola ; Calzetta, Luigino ; Manzetti, Gian Marco

INTRODUCTION:

Severe asthma patients often remain uncontrolled despite high-intensity therapies. Biological therapies targeting thymic stromal lymphopoietin (TSLP), a key player in asthma pathogenesis, have emerged as potential options. Currently, the only TSLP inhibitor approved for the treatment of severe asthma is the immunoglobulin G (IgG) 2λ anti-TSLP monoclonal antibody (mAb) tezepelumab.

AREAS COVERED:

This systematic review assesses the efficacy and safety of investigational TSLP inhibitors across different stages of development for asthma treatment.

EXPERT OPINION:

TSLP contributes to airway inflammation, making it a pivotal therapeutic target. Ecleralimab, an inhaled antibody fragment antigen binding, shows promising evidence in enhancing efficacy and reducing systemic adverse events. SAR443765, with its NANOBODY® formulation and bispecific inhibition of TSLP and IL-13, offers improved tissue penetration and efficacy. The mAB TQC2731 exhibits high in vitro bioactivity, and the strength of the mAb UPB-101 is to act against the TSLP receptor. Some studies include mild and moderate asthma patients, suggesting the potential for extending biological therapy to non-severe patients. This systematic review highlights the potential of TSLP inhibitors as valuable additions to asthma treatment, even in milder forms of the disease. Future research and cost-reduction efforts are needed to expanding access to these promising therapies.

01 Mar 2023·The European respiratory journal

Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma

Article

Author: Jones, Ieuan ; Watz, Henrik ; Kornmann, Oliver ; O'Byrne, Paul M ; Hohlfeld, Jens M ; Davis, Beth E ; Cabanski, Maciej ; Leigh, Richard ; Pertel, Peter E ; Korn, Stephanie ; Jain, Monish ; Mayers, Irvin ; Lecot, Jean R ; Cockcroft, Donald W ; Grant, Sarah S ; Boulet, Louis-Philippe ; FitzGerald, J Mark ; Cao, Hui ; Gauvreau, Gail M

Background:

Thymic stromal lymphopoietin (TSLP) is a key upstream regulator driving allergic inflammatory responses. We evaluated the efficacy and safety of ecleralimab, a potent inhaled neutralising antibody fragment against human TSLP, using allergen inhalation challenge (AIC) in subjects with mild atopic asthma.

Methods:

This was a 12-week, randomised, double-blind, placebo-controlled, parallel-design, multicentre allergen bronchoprovocation study conducted at 10 centres across Canada and Germany. Subjects aged 18–60 years with stable mild atopic asthma were randomised (1:1) to receive 4 mg once-daily inhaled ecleralimab or placebo. Primary end-points were the allergen-induced change in forced expiratory volume in 1 s (FEV1) during the late asthmatic response (LAR) measured by area under the curve (AUC3–7h) and maximum percentage decrease (LAR%) on day 84, and the safety of ecleralimab. Allergen-induced early asthmatic response (EAR), sputum eosinophils and fractional exhaled nitric oxide (FENO) were secondary and exploratory end-points.

Results:

28 subjects were randomised to ecleralimab (n=15) or placebo (n=13). On day 84, ecleralimab significantly attenuated LAR AUC3–7hby 64% (p=0.008), LAR% by 48% (p=0.029), and allergen-induced sputum eosinophils by 64% at 7 h (p=0.011) and by 52% at 24 h (p=0.047) post-challenge. Ecleralimab also numerically reduced EAR AUC0–2h(p=0.097) and EAR% (p=0.105).FENOlevels were significantly reduced from baseline throughout the study (p<0.05), except at 24 h post-allergen (day 43 and day 85). Overall, ecleralimab was safe and well tolerated.

Conclusion:

Ecleralimab significantly attenuated allergen-induced bronchoconstriction and airway inflammation, and was safe in subjects with mild atopic asthma.

News (Medical) associated with Ecleralimab

09 Jan 2024

·www.fiercebiotech.com

GSK, moving fast to buy Aiolos, pays $1B to challenge Amgen, AstraZeneca for asthma market

GSK moved quickly to add the long-acting anti-TSLP antibody to its portfolio, Well, that was fast. Seventy seven days after Aiolos Bio launched to the public, GSK has disclosed a deal to buy the biotech and its phase 2 asthma treatment for $1 billion upfront and up to $400 million in regulatory milestones. Aiolos broke cover in late October, launching with a $245 million series A round co-led by Atlas Venture, Bain Capital Life Sciences, Forbion and Sofinnova Investments. The biotech raised the money to fund the development of a long-acting anti-TSLP monoclonal antibody, AIO-001, that it picked up from Jiangsu Hengrui Pharmaceuticals two months earlier. Other companies got to the TSLP opportunity before GSK. Amgen and AstraZeneca won FDA approval for an anti-TSLP antibody, Tezspire, late in 2021. Novartis hung a 'for sale' sign on its midphase TSLP prospect, CSJ117, months after the FDA authorized Tezspire. GSK has weighed up the competition and bet up to $1.4 billion on AIO-001. In a statement, Tony Wood, chief scientific officer at GSK, called AIO-001 a potentially best-in-class medicine that could expand the company’s biologics portfolio to the 40% of severe asthma patients with low T2 inflammation. Post-hoc analyses of phase 2/3 trials of Tezspire linked the antibody to reductions in exacerbations in T2 low asthmas, a subgroup that other drugs, including GSK’s Nucala and phase 3 prospect depemokimab, aren’t designed to treat. Tezspire’s broad efficacy led the FDA to make it the first asthma drug approved for severe asthma without phenotypic limitations, such as eosinophilic, or biomarker restrictions. The belief that AIO-001 can improve on Tezspire rests, in part, on its dosing schedule. Tezspire is given subcutaneously once a month. GSK believes the “enhanced potency and half-life extension technology” of AIO-001 could support dosing every six months. The Big Pharma’s work on the HIV drugs Cabenuva and Apretude has shown how longer-lasting medicines can win market share. GSK, which will acquire rights to AIO-001 outside of Greater China, plans to run a phase 2 trial in adults with asthma and is assessing whether to expand development into other indications, including chronic rhinosinusitis with nasal polyps. Amgen and AstraZeneca are running phase 3 trials of Tezspire in people with chronic rhinosinusitis and eosinophilic esophagitis. The deal represents another successful exit for Aiolos CEO Khurem Farooq, who co-founded the biotech with Tony Adamis, M.D., after leading Gyroscope Therapeutics to an $800 million takeover by Novartis.

Drug ApprovalPhase 3AcquisitionPhase 2Immunotherapy

24 Oct 2023

·firstwordpharma.com

Aiolos debuts with $245 million to advance twice-yearly antibody for asthma

Aiolos Bio emerged from stealth mode on Tuesday with an oversubscribed $245-million Series A financing and plans to advance its lead drug candidate AIO-001 into mid-stage testing for moderate-to-severe asthma. The anti-TSLP monoclonal antibody, which was licensed from Jiangsu Hengrui Pharmaceuticals in August, has the potential to be administered just twice per year due to its differentiated potency and long half-life, according to the start-up.Co-founder and board member Tony Adamis said "we believe [AIO-001] has the potential to help patients achieve better disease control with fewer injections, so their asthma doesn't have to play such a central role in their lives. We are working to begin our Phase II trial as soon as possible."AIO-001 was originally developed through early clinical stages by Jiangsu Hengrui, which retains commercialisation rights in China, with Aiolos holding exclusive rights to the drug outside the country. The start-up says AIO-001 has demonstrated "in multiple clinical studies…encouraging safety, tolerability, pharmacokinetics and biological activity in healthy volunteers and asthma patients, with low immunogenicity."Edge with dosingAmgen and AstraZeneca currently market the anti-TSLP antibody Tezspire (tezepelumab) for patients with severe asthma based on data showing that it significantly reduced annualised asthma exacerbation rates at 52 weeks, with benefit seen across subtypes, including blood eosinophil count. Tezspire is administered by subcutaneous injection every four weeks. TSLP inhibition is also currently under investigation for other immune conditions such as chronic obstructive pulmonary disorder and chronic spontaneous urticaria.The Series A round in Aiolos was co-led by Atlas Venture, Bain Capital, Forbion and Sofinnova. The drugmaker will use the capital to start a Phase II trial of AIO-001 and explore additional indications.Industry veteran John Milligan, former CEO of Gilead Sciences, has been appointed chairman of the board of directors. He joins founding CEO Khurem Farooq, formerly the CEO of Gyroscope Therapeutics and the head of the immunology and ophthalmology business at Roche's Genentech unit.Other companies working on anti-TSLP antibodies include Sanofi, which has a Phase I asset dubbed SAR443765, a bifunctional compound that also blocks IL-13. Meanwhile, Novartis terminated development of its inhaled anti-TSLP therapy ecleralimab. One key opinion leader (KOL) interviewed for a FirstWord report this year noted that the Swiss drugmaker "understood that the important thing is to target the nose and with the inhaled route you are not targeting the nose but only the airways."

Phase 1Phase 2Executive Change

02 Mar 2023

·www.prnewswire.com

Propulsion of Asthma Pipeline as Novel and Extensive 95+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

Asthma is a chronic disease that affects a substantial number of patients worldwide, including children, a number of pharmaceutical companies are involved in developing drugs for asthma. This involvement includes the development of novel therapies that being evaluated in different phases of development. LAS VEGAS, March 2, 2023 /PRNewswire/ -- DelveInsight's ' Asthma Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline asthma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the asthma pipeline domain. Key Takeaways from the Asthma Pipeline Report DelveInsight's asthma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for asthma treatment. Key asthma companies such as Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others are evaluating new asthma drugs to improve the treatment landscape. Promising asthma pipeline therapies in various stages of development include CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others. In February 2023, UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase III clinical development. Dexpramipexole is beig developed by Areteia Therapeutics to inhibit the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. In February 2023, Pulmatrix, Inc. announced that the first patient dosed in a Phase IIb trial evaluating safety and efficacy of PUR1900 in subjects with Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. PUR1900 is the company's iSPERSE-enabled dry powder formulation of itraconazole, developed for inhaled pulmonary delivery. The Phase II trial is designed as a randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and duration of treatment with itraconazole, administered as a dry powder for inhalation (PUR1900). Endpoints include safety, tolerability, and potential efficacy outcomes in adult patients with asthma and ABPA. Olatec Therapeutics LLC in February 2023 completed the $40 million Series A round financing, the final closing of which was led by Sanders Morris Harris ("SMH"). Participation in the round came from both existing investors as well as new investors identified by each of Sanders Morris Harris, Advection Growth Capital, and the Company. Proceeds will be principally used to advance Olatec's lead compound, dapansutrile, into later-stage clinical development. Dapansutrile has also been observed to have anti-inflammatory properties and other promising activity in a broad spectrum of over 20 preclinical animal models, including arthritis, asthma, acute myocardial infarction (AMI), heart failure, contact dermatitis, multiple sclerosis, melanoma, pancreatic and breast cancers, spinal cord injury (SCI), Parkinson's and Alzheimer's disease. In January 2023, Avillion LLP, announced that the US Food and Drug Administration (FDA) approved AstraZeneca's Airsupra (albuterol/budesonide, formerly known as PT027) for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS). Upstream Bio, in August 2022, initiated a Phase Ib multiple ascending dose study of UPB-101 in asthma patients and successful dosing of the first patient. UPB-101 is a monoclonal antibody designed to block the thymic stromal lymphopoietin receptor (TLSPR) and thus inhibit TSLP-driven inflammation. TSLP is a cytokine and a key driver of inflammatory response in asthma and other allergic and inflammatory diseases. Request a sample and discover the recent advances in asthma drug treatment @ Asthma Pipeline Report The asthma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage asthma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the asthma clinical trial landscape. Asthma Overview Asthma is a chronic disease of the airways. Asthma is characterized by airway inflammation and spasm. Airways are tubes that transport air into and out of the lungs. Asthmatics cause the inside walls of the airways to become sore and swollen. Because of inflammation and tightening of the muscles surrounding the small airways, the airways in the lungs become narrow. Asthma symptoms include coughing, wheezing, shortness of breath, and chest tightness. Asthma symptoms differ from person to person. A person may have infrequent asthma attacks, have symptoms only when exercising, or have symptoms all of the time. Asthma symptoms are similar to those of many respiratory infections. A careful clinical history is the first step in asthma diagnosis; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on quality of life. Find out more about drugs for asthma @ New Asthma Drugs A snapshot of the Asthma Pipeline Drugs mentioned in the report: Learn more about the emerging asthma pipeline therapies @ Asthma Clinical Trials Asthma Therapeutics Assessment The asthma pipeline report proffers an integral view of asthma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Asthma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Immunomodulators, Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists, Interleukin 5 receptor antagonists, Matrix metalloproteinase 12 inhibitors, Aldehyde inhibitors, Bacteria replacements; Microbiome modulators, Thymic stromal lymphopoietin inhibitors; Thymic stromal lymphopoietin modulators, Interleukin-33 inhibitors, Inflammasome inhibitors; Interleukin 1 beta inhibitors; Interleukin 18 inhibitors; Interleukin inhibitors; NLRP3 protein inhibitors, Interleukin-17 inhibitors Key Asthma Companies: Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Tetherex Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others. Key Asthma Pipeline Therapies: CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others. Dive deep into rich insights for new drugs for asthma treatment; visit @ Asthma Medications Table of Contents For further information on the asthma pipeline therapeutics, reach out @ Asthma Drug Treatment Related Reports Severe Asthma Market Severe Asthma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key severe asthma companies, including AstraZeneca, Novartis, Sanofi, among others. Asthma Pipeline Asthma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key asthma companies, including GSK, AstraZeneca, Teva Pharmaceuticals, among others. Severe Asthma Pipeline Severe Asthma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key severe asthma companies, including AstraZeneca, Novartis, Sanofi, among others. Chronic Obstructive Pulmonary Disease Epidemiology Forecast Chronic Obstructive Pulmonary Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the chronic obstructive pulmonary disease epidemiology trends. Chronic Obstructive Pulmonary Disease Market Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease companies, including Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma, among others. Acute Respiratory Distress Syndrome Pipeline Acute Respiratory Distress Syndrome Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key acute respiratory distress syndrome companies, including Bayer, Faron Pharmaceuticals, BioMarck Pharmaceuticals, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Blogs Emerging Therapies for Severe Asthma Treatment COPD Treatment Market COPD Epidemiological Trends Chronic Respiratory Disease Market Promising Therapies in the ARDS Market Rising Acute Respiratory Distress Syndrome Prevalence ARDS Market Outlook Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

Phase 2Drug ApprovalPhase 3Phase 1

100 Deals associated with Ecleralimab

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 2	United States	Novartis Pharmaceuticals Corp.	24 Sep 2021
Pulmonary Disease, Chronic Obstructive	Phase 2	Japan	Novartis Pharmaceuticals Corp.	24 Sep 2021
Pulmonary Disease, Chronic Obstructive	Phase 2	Australia	Novartis Pharmaceuticals Corp.	24 Sep 2021
Pulmonary Disease, Chronic Obstructive	Phase 2	Canada	Novartis Pharmaceuticals Corp.	24 Sep 2021
Pulmonary Disease, Chronic Obstructive	Phase 2	Czechia	Novartis Pharmaceuticals Corp.	24 Sep 2021
Pulmonary Disease, Chronic Obstructive	Phase 2	Hungary	Novartis Pharmaceuticals Corp.	24 Sep 2021
Asthma	Phase 2	United States	Novartis Pharmaceuticals Corp.	09 Sep 2020
Asthma	Phase 2	Japan	Novartis Pharmaceuticals Corp.	09 Sep 2020
Asthma	Phase 2	Argentina	Novartis Pharmaceuticals Corp.	09 Sep 2020
Asthma	Phase 2	Belgium	Novartis Pharmaceuticals Corp.	09 Sep 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04410523 (CTgov)	Phase 2	Asthma	335	Placebo+CSJ117 (CSJ117 0.5mg)	fndkvndklr(fbkjymuuna) = gvrmreorgx wegcnmifnk (ynkrtsjisx, 0.0445) View more	-	07 Aug 2023
				Placebo+CSJ117 (CSJ117 1mg)	fndkvndklr(fbkjymuuna) = pktxngkljs wegcnmifnk (ynkrtsjisx, 0.0446) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis